MINI FUTURE LONG - ELANCO ANIMAL HEALTH Share Price

Certificat

DE000PE5UHT8

Delayed Deutsche Boerse AG 12:51:14 03/07/2024 pm IST
0.57 EUR -1.72% Intraday chart for MINI FUTURE LONG - ELANCO ANIMAL HEALTH
Current month-4.92%
1 month-36.26%
Date Price Change
03/24/03 0.57 -1.72%
02/24/02 0.58 -1.69%
01/24/01 0.59 -3.28%
28/24/28 0.61 +3.39%
27/24/27 0.59 -37.23%

Delayed Quote Deutsche Boerse AG

Last update July 03, 2024 at 12:51 pm IST

More quotes

Static data

Product typeKnock-Out mit Stop Loss
Buy / SellCALL
Underlying ELANCO ANIMAL HEALTH INCORPORATED
IssuerLogo Issuer BNP Paribas BNP Paribas
WKN PE5UHT
ISINDE000PE5UHT8
Date issued 30/10/2023
Strike 7.996 $
Maturity Unlimited
Parity 10 : 1
Emission price 0.11
Emission volume N/A
Settlement Barausgleich
Currency EUR

Technical Indicators

Highest since issue 1.01
Lowest since issue 0.12
Spread 0.02
Spread %3.39%

Company Profile

Elanco Animal Health Incorporated is an animal health company. The Company is focused in delivering products and services to prevent and treat disease in farm animals and pets. Its portfolio serves animals across its core species consisting of dogs, cats and cattle, poultry, swine, sheep and aqua. It offers products in two primary categories: Pet Health and Farm Animal. Its Pet Health portfolio is focused on parasiticides, vaccines and therapeutics. Its Pet Health portfolio products that protect pets from fleas, ticks and internal parasites. Its Farm Animal portfolio of products is primarily focused on cattle, swine, poultry, and aquaculture. Its Pet Health products include Advantage Family, Atopica, Claro/ Neptra, Credelio Family, Drontal Family, Galliprant, Interceptor Plus, Milbemax, Onsior, Seresto, Trifexis, and TruCan. Its Farm Animal products include AviPro, Baycox, Catosal, Comforta, Denagard, Experior, Hemicell, Maxiban, Monteban, Pulmotil, Rumensin, and others.
Sector
-
More about the company

Ratings for Elanco Animal Health Incorporated

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Consensus: Elanco Animal Health Incorporated

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
14.01 USD
Average target price
19.3 USD
Spread / Average Target
+37.73%
Consensus